Korro Bio, Inc. Proceeds from Issuance of Private Placement
Korro Bio, Inc. (KRRO) reported Proceeds from Issuance of Private Placement of $5.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-08-06
- Korro Bio, Inc. proceeds from issuance of private placement for the quarter ending 2026-06-30 was -$21.00K.
- Korro Bio, Inc. proceeds from issuance of private placement for the quarter ending 2026-03-31 was $5.04M.
- Korro Bio, Inc. proceeds from issuance of private placement for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Korro Bio, Inc. proceeds from issuance of private placement for the quarter ending 2025-09-30 was $0.00.
- Korro Bio, Inc. proceeds from issuance of private placement for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Korro Bio, Inc. proceeds from issuance of private placement for fiscal 2024 was $67.39M.
- Korro Bio, Inc. proceeds from issuance of private placement for fiscal 2023 was $0.00.
- Korro Bio, Inc. proceeds from issuance of private placement for fiscal 2020 was $40.14M.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.02M 10-Q · filed 2026-08-06 | $5.02M derived: sum of 3 quarters · filed 2026-08-06 | $5.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.04M 10-Q · filed 2026-05-07 | $5.04M derived: sum of 2 quarters · filed 2026-05-07 | $5.04M derived: sum of 3 quarters · filed 2026-05-07 | $5.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $0.00 10-Q · filed 2025-11-12 | $1.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $1.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $1.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.00K derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.00K derived: sum of 2 quarters · filed 2026-03-12 | $67.39M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $67.38M 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $67.38M 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-18 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $40.14M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $40.14M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |